Royalty Pharma Q2 Earnings Call Highlights

Royalty Pharma NASDAQ: RPRX raised its 2026 outlook for the second consecutive quarter after reporting higher second-quarter royalty receipts, continued capital deployment and progress across its development-stage pipeline.

MarketBeat • Aug 5, 2026

Royalty Pharma plc (RPRX) Q2 2026 Earnings Call Transcript

Royalty Pharma plc (RPRX) Q2 2026 Earnings Call Transcript

Seeking Alpha • Aug 5, 2026

Royalty Pharma reports second quarter 2026 results

Portfolio Receipts growth of 6% to $773 million; Royalty Receipts growth of 14% Net cash provided by operating activities of $728 million Raised full year 2026 guidance: Portfolio Receipts expected to be $3,400 million to $3,500 million NEW YORK, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the second quarter of 2026 and raised full year 2026 guidance for Portfolio Receipts. “Royalty Pharma delivered strong second quarter results with Royalty Receipts growth of 14%,” said Pablo Legorreta, Royalty Pharma's Chief Executive Officer and Chairman of the Board.

GlobeNewsWire • Aug 5, 2026

Royalty Pharma (RPRX) Tops Q2 Earnings and Revenue Estimates

Royalty Pharma (RPRX) came out with quarterly earnings of $1.32 per share, beating the Zacks Consensus Estimate of $1.27 per share. This compares to earnings of $1.14 per share a year ago.

Zacks Investment Research • Aug 5, 2026

Royalty Pharma (RPRX) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Although the revenue and EPS for Royalty Pharma (RPRX) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks Investment Research • Aug 5, 2026

Gear Up for Royalty Pharma (RPRX) Q2 Earnings: Wall Street Estimates for Key Metrics

Beyond analysts' top-and-bottom-line estimates for Royalty Pharma (RPRX), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2026.

Zacks Investment Research • Aug 4, 2026

Royalty Pharma appoints Greg Raskin as Senior Vice President, Head of Academic Initiatives

NEW YORK, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Greg Raskin, M.D. as Senior Vice President, Head of Academic Initiatives, effective August 2026. Greg will lead Royalty Pharma's outreach efforts with academic and non-profit institutions as well as oversee the Royalty Pharma Translational Prize. Greg joins Royalty Pharma after nearly three decades at the intersection of science, medicine and investing, and most recently served as Senior Vice President, Technology Development at Memorial Sloan Kettering Cancer Center.

GlobeNewsWire • Aug 3, 2026

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

Zacks Investment Research • Aug 3, 2026

Royalty Pharma (RPRX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Royalty Pharma (RPRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research • Jul 29, 2026

Royalty Pharma acquires royalty interest in AstraZeneca's cliramitug for up to $425 million from Neurimmune

NEW YORK, July 22, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired a portion of Neurimmune's royalty interest in AstraZeneca's cliramitug for up to $425 million, including $125 million upfront.

GlobeNewsWire • Jul 22, 2026